CO2021011042A2 - Sales de sulcardina - Google Patents
Sales de sulcardinaInfo
- Publication number
- CO2021011042A2 CO2021011042A2 CONC2021/0011042A CO2021011042A CO2021011042A2 CO 2021011042 A2 CO2021011042 A2 CO 2021011042A2 CO 2021011042 A CO2021011042 A CO 2021011042A CO 2021011042 A2 CO2021011042 A2 CO 2021011042A2
- Authority
- CO
- Colombia
- Prior art keywords
- salts
- sulcardine
- sulcardine salts
- methods
- sulfuric acid
- Prior art date
Links
- SYZGIWXQGIBJGN-UHFFFAOYSA-N hbi-3000 Chemical class C1=CC(OC)=CC=C1S(=O)(=O)NCC1=CC(CN2CCCC2)=C(O)C(CN2CCCC2)=C1 SYZGIWXQGIBJGN-UHFFFAOYSA-N 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/42—Separation; Purification; Stabilisation; Use of additives
- C07C303/44—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials Engineering (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798467P | 2019-01-29 | 2019-01-29 | |
| US202062959687P | 2020-01-10 | 2020-01-10 | |
| PCT/US2020/015370 WO2020159959A1 (en) | 2019-01-29 | 2020-01-28 | Sulcardine salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021011042A2 true CO2021011042A2 (es) | 2022-01-17 |
Family
ID=69724142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0011042A CO2021011042A2 (es) | 2019-01-29 | 2021-08-23 | Sales de sulcardina |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11426382B2 (https=) |
| EP (1) | EP3917921A1 (https=) |
| JP (3) | JP2022518906A (https=) |
| KR (2) | KR102405199B1 (https=) |
| CN (2) | CN115385871A (https=) |
| AU (1) | AU2020216925B2 (https=) |
| BR (1) | BR112021014640A8 (https=) |
| CA (1) | CA3128152A1 (https=) |
| CL (1) | CL2021001968A1 (https=) |
| CO (1) | CO2021011042A2 (https=) |
| IL (1) | IL285184B2 (https=) |
| MX (2) | MX2021009033A (https=) |
| PH (1) | PH12021551818A1 (https=) |
| SG (1) | SG11202108160YA (https=) |
| WO (1) | WO2020159959A1 (https=) |
| ZA (2) | ZA202105344B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11364223B2 (en) | 2018-12-13 | 2022-06-21 | Huyabio International, Llc | Sulcardine administration for treatment of acute atrial fibrillation |
| CN115385871A (zh) * | 2019-01-29 | 2022-11-25 | 沪亚生物国际有限公司 | 舒欣啶盐 |
| CA3182015A1 (en) | 2020-06-12 | 2021-12-16 | Gary Elliott | Sulcardine administration for treatment of acute atrial fibrillation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1172908C (zh) * | 1999-12-10 | 2004-10-27 | 中国科学院上海药物研究所 | N-取代苄基或苯基芳香磺酰胺化合物及其用途 |
| CN1299813C (zh) | 2004-12-28 | 2007-02-14 | 华南理工大学 | 自动撕膜落料及多样性搅拌的机构和控制装置 |
| CN1939298A (zh) * | 2005-09-29 | 2007-04-04 | 中国科学院上海药物研究所 | 硫酸舒欣啶固体和靶向制剂及其制备方法 |
| CN102665714A (zh) | 2009-11-17 | 2012-09-12 | 沪亚生物国际有限责任公司 | 心房纤颤的治疗 |
| EP2501380B1 (en) * | 2009-11-17 | 2016-01-27 | Huya Bioscience International LLC | Slow infusion of sulcardine and its salts |
| MA41599A (fr) * | 2015-02-26 | 2018-01-02 | Array Biopharma Inc | Formes cristallines d'un composé pyrrolopyridine |
| CA3254279A1 (en) | 2015-06-03 | 2025-03-18 | Triastek, Inc. | PHARMACEUTICAL FORMS AND RELATED USES |
| CA3023278C (en) | 2016-05-05 | 2019-04-30 | Triastek, Inc. | Controlled release dosage form |
| KR20190107712A (ko) | 2017-01-26 | 2019-09-20 | 트리아스텍 인코포레이티드 | 특정 위장 부위에서의 제어 방출의 투여 형태 |
| CA3054403A1 (en) * | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
| US11364223B2 (en) | 2018-12-13 | 2022-06-21 | Huyabio International, Llc | Sulcardine administration for treatment of acute atrial fibrillation |
| CN115385871A (zh) | 2019-01-29 | 2022-11-25 | 沪亚生物国际有限公司 | 舒欣啶盐 |
-
2020
- 2020-01-28 CN CN202211089980.8A patent/CN115385871A/zh active Pending
- 2020-01-28 US US16/775,142 patent/US11426382B2/en active Active
- 2020-01-28 IL IL285184A patent/IL285184B2/en unknown
- 2020-01-28 AU AU2020216925A patent/AU2020216925B2/en active Active
- 2020-01-28 KR KR1020217027357A patent/KR102405199B1/ko active Active
- 2020-01-28 CN CN202080004796.1A patent/CN112638903B/zh active Active
- 2020-01-28 EP EP20707973.2A patent/EP3917921A1/en active Pending
- 2020-01-28 CA CA3128152A patent/CA3128152A1/en active Pending
- 2020-01-28 SG SG11202108160YA patent/SG11202108160YA/en unknown
- 2020-01-28 KR KR1020227017874A patent/KR102697726B1/ko active Active
- 2020-01-28 JP JP2021542541A patent/JP2022518906A/ja active Pending
- 2020-01-28 MX MX2021009033A patent/MX2021009033A/es unknown
- 2020-01-28 WO PCT/US2020/015370 patent/WO2020159959A1/en not_active Ceased
- 2020-01-28 BR BR112021014640A patent/BR112021014640A8/pt unknown
- 2020-01-28 PH PH1/2021/551818A patent/PH12021551818A1/en unknown
- 2020-10-23 US US17/079,347 patent/US11020374B2/en active Active
-
2021
- 2021-07-27 CL CL2021001968A patent/CL2021001968A1/es unknown
- 2021-07-27 MX MX2023014776A patent/MX2023014776A/es unknown
- 2021-07-28 ZA ZA2021/05344A patent/ZA202105344B/en unknown
- 2021-08-23 CO CONC2021/0011042A patent/CO2021011042A2/es unknown
- 2021-10-05 ZA ZA2021/07474A patent/ZA202107474B/en unknown
-
2022
- 2022-07-11 US US17/862,117 patent/US20250144072A9/en active Pending
-
2023
- 2023-11-02 JP JP2023188791A patent/JP2024039020A/ja active Pending
-
2025
- 2025-07-07 JP JP2025114666A patent/JP2025165933A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022018811A2 (es) | Inhibidores de la proteína kras g12c y usos de estos | |
| CY1126110T1 (el) | Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6 | |
| MX2021009276A (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2. | |
| MX2020013726A (es) | Compuestos antagonistas de pcsk9. | |
| MX383856B (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| CL2017002727A1 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| MX389349B (es) | Derivados de ácido borónico y usos terapéuticos de los mismos. | |
| MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| CL2021002309A1 (es) | Compuestos útiles en la terapia del vih | |
| MX376584B (es) | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos | |
| CL2017003245A1 (es) | Derivados de piperidina 1,4-sustituidos | |
| UY37997A (es) | Agentes antivirales contra la hepatitis b | |
| CO2021011042A2 (es) | Sales de sulcardina | |
| MX2024006689A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| BR112017026159A2 (pt) | inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer | |
| BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
| BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
| JOP20200100A1 (ar) | مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3 | |
| BR112015022577A2 (pt) | moduladores ship1 e métodos relacionados a esse | |
| MX391620B (es) | Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). | |
| BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
| MX389581B (es) | Compuestos que contienen nitrogeno sustituido. |